Neurology A multicenter, double blinded, randomized trial–National Institute of Neurological Disorders and Stroke which evaluated the effects of tPA therapy in Pts with stroke. SeeThrombolytic therapy, tPA. McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc...
Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke. Stroke 1993; 24: 1000–1004. CrossRef NINDS rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581–1587. Kwiatkowski TG, Libman RB, Frankel M, Tilley ...
pointsThe American Heart Association rated the thrombolytic agent alteplase (tPA) as a class I (definitely recommended) intervention for stroke despite controversy about its safety and efficacyMost of the association's stroke experts have ties to the manufacturers of 鈥 Correspondence to: Dr ...
NINDS tPA Stroke Trial Investigators. Therefore, we proposed to use data from the National Institute of Neurological Disorders and Stroke (NINDS) tPA Stroke Trial to determine whether the ... P Lyden,M Lu,C Jackson,... - 《Stroke》 被引量: 1959发表: 1999年 A modified National Institutes ...
but the results of each trial did not support its use beyond 3 hours.都是证明阿替普酶静脉溶栓...
less likely to have a favorable outcome at 3 months (P < 0.01) than those who were hypertensive and did not receive antihypertensive therapy.The frequency of hypertension and the use of antihypertensive therapy were similar between the tPA and placebo groups in the NINDS rt-PA Stroke Trial. In...
No differential effect of tPA based on final stroke etiologic subtype: A reanalysis of the NINDS tPA trialS.R., MartiniS.D., YeattsS.R., BelagageP., Khatri
METHODS: We performed an exploratory factor analysis of NIHSS data from Part 1 (n=291) of the NINDS tPA Stroke Trial to derive a hypothesized underlying factor structure. We then performed a confirmatory factor analysis of this structure using NIHSS data from Part 2 of the same trial (n=...
While the NINDS trial neither supports nor refutes the possibility of any benefit (or harm) from tPA in AIS, it does show that the magnitude of effect is likely to be very small, regardless of its direction. In addition, the study data contradict the "time is brain" hypothesis, and ...
Results - Historically, the intent of this exclusion criterion within the NINDS recombinant tPA Stroke Trial was to avoid treatment of transient ischemic attacks - who would have recovered completely without treatment. There was unanimous consensus that, in the absence of other contraindications, ...